Trial Profile
Janus Kinase Inhibitor (Baricitinib) for Aicardi Goutières Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Encephalopathy; Leukoencephalopathies; Neurological disorders
- Focus Therapeutic Use
- 16 Jun 2023 Planned number of patients changed from 50 to 55.
- 29 Jul 2021 Planned number of patients changed from 100 to 50.
- 11 Sep 2020 Status changed from recruiting to active, no longer recruiting.